Cargando…

MUC1-C ACTIVATES THE TAK1 INFLAMMATORY PATHWAY IN COLON CANCER

The mucin 1 (MUC1) oncoprotein has been linked to the inflammatory response by promoting cytokine-mediated activation of the NF-κB pathway. The TGF-β-activated kinase 1 (TAK1) is an essential effector of proinflammatory NF-κB signaling that also regulates cancer cell survival. The present studies de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takahashi, Hidekazu, Jin, Caining, Rajabi, Hasan, Pitroda, Sean, Alam, Maroof, Ahmad, Rehan, Raina, Deepak, Hasegawa, Masanori, Suzuki, Yozo, Tagde, Ashujit, Bronson, Roderick T., Weichselbaum, Ralph, Kufe, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530107/ https://www.ncbi.nlm.nih.gov/pubmed/25659581 http://dx.doi.org/10.1038/onc.2014.442

Ejemplares similares

DNA METHYLATION BY DNMT1 AND DNMT3b METHYLTRANSFERASES IS DRIVEN BY THE MUC1-C ONCOPROTEIN IN HUMAN CARCINOMA CELLS
por: Rajabi, Hasan, et al.
Publicado: (2016)

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
por: Hasegawa, Masanori, et al.
Publicado: (2016)

MUC1-C drives DNA methylation in cancer
por: Rajabi, Hasan, et al.
Publicado: (2016)

MUC1-C ACTIVATES BMI1 IN HUMAN CANCER CELLS
por: Hiraki, Masayuki, et al.
Publicado: (2016)

Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells
por: Alam, Maroof, et al.
Publicado: (2014)

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma
por: Tagde, Ashujit, et al.
Publicado: (2017)

Cooperative Interaction between the MUC1-C Oncoprotein and the Rab31 GTPase in Estrogen Receptor-Positive Breast Cancer Cells
por: Jin, Caining, et al.
Publicado: (2012)

MUC1-C INTEGRATES PD-L1 INDUCTION WITH REPRESSION OF IMMUNE EFFECTORS IN NON-SMALL CELL LUNG CANCER
por: Bouillez, Audrey, et al.
Publicado: (2017)

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer
por: Hiraki, Masayuki, et al.
Publicado: (2018)

MUC1-C activates EZH2 expression and function in human cancer cells
por: Rajabi, Hasan, et al.
Publicado: (2017)

MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia
por: Tagde, Ashujit, et al.
Publicado: (2016)

MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors
por: Hiraki, Masayuki, et al.
Publicado: (2016)

COOPERATIVITY OF THE MUC1 ONCOPROTEIN AND STAT1 PATHWAY IN POOR PROGNOSIS HUMAN BREAST CANCER
por: Khodarev, Nikolai, et al.
Publicado: (2009)

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
por: Kharbanda, Akriti, et al.
Publicado: (2014)

Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer
por: Ahmad, Rehan, et al.
Publicado: (2017)

TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS
por: Raina, Deepak, et al.
Publicado: (2013)

MUC1-C Oncoprotein Regulates Glycolysis and Pyruvate Kinase m2 Activity in Cancer Cells
por: Kosugi, Michio, et al.
Publicado: (2011)

TARGETING THE eIF4A RNA HELICASE BLOCKS TRANSLATION OF THE MUC1-C ONCOPROTEIN
por: Jin, Caining, et al.
Publicado: (2012)

MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients
por: MacDermed, Dhara M, et al.
Publicado: (2010)

MUC1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism
por: Stroopinsky, Dina, et al.
Publicado: (2018)

MUC1-C REPRESSES THE RASSF1A TUMOR SUPPRESSOR IN HUMAN CARCINOMA CELLS
por: Rajabi, Hasan, et al.
Publicado: (2019)

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2020)

MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas
por: Luan, Zhou, et al.
Publicado: (2021)

Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells
por: Rajabi, Hasan, et al.
Publicado: (2019)

Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2020)

Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target
por: Raina, Deepak, et al.
Publicado: (2015)

Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment
por: Morimoto, Yoshihiro, et al.
Publicado: (2022)

Emergence of MUC1 in Mammals for Adaptation of Barrier Epithelia
por: Kufe, Donald W.
Publicado: (2022)

Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer
por: Fushimi, Atsushi, et al.
Publicado: (2022)

Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer
por: Kufe, Donald
Publicado: (2023)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells
por: Bhattacharya, Atrayee, et al.
Publicado: (2022)

Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells
por: Kufe, Donald W.
Publicado: (2022)

Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression
por: Yamashita, Nami, et al.
Publicado: (2022)

MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells
por: Morimoto, Yoshihiro, et al.
Publicado: (2023)

MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells
por: Hagiwara, Masayuki, et al.
Publicado: (2021)

microRNAs and oligometastasis
por: Khodarev, Nikolai N., et al.
Publicado: (2015)

Oligometastatic prostate cancer: Reality or figment of imagination?
por: Foster, Corey C., et al.
Publicado: (2018)

Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold
por: Turchan, William Tyler, et al.
Publicado: (2021)

Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy
por: Turchan, William Tyler, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6isn07q37f0rabner0qo59qrnl